An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics Carlos A. Rodriguez,a Maria Agudelo,a,c Javier M. Gonzalez,a,c Omar Vesga,a,b,c Andres F. Zuluagaa GRIPE (Grupo Investigador de Problemas en Enfermedades Infecciosas), Department of Pharmacology and Toxicology,a and Department of Internal Medicine,b School of Medicine, Universidad de Antioquia, Medellín, Colombia; Infectious Diseases Unit, Hospital Universitario San Vicente Fundación, Medellín, Colombiac Negligible in vivo growth of enterococci and high-level dispersion of data have led to inaccurate estimations of antibiotic phar- macodynamics (PD). Here we improved an in vivo model apt for PD studies by optimizing the in vitro culture conditions for enterococci. The PD of vancomycin (VAN), ampicillin-sulbactam (SAM), and piperacillin-tazobactam (TZP) against enterococci were determined in vivo, comparing the following different conditions of inoculum preparation: aerobiosis, aerobiosis plus mu- cin, and anaerobiosis plus mucin. Drug exposure was expressed as the ratio of the area under the concentration-time curve for the free, unbound fraction of the drug to the MIC (fAUC/MIC) (VAN) or the time in a 24-h period that the drug concentration for the free, unbound fraction exceeded the MIC under steady-state pharmacokinetic conditions (fT>MIC) (SAM and TZP) and linked to the change in log10 CFU/thigh. Only anaerobiosis plus mucin enhanced the in vivo growth, yielding significant PD pa- rameters with all antibiotics. In conclusion, robust in vivo growth of enterococci was crucial for better determining the PD of tested antibacterial agents, and this was achieved by optimizing the procedure for preparing the inoculum. Enterococci are commensal organisms in the gastrointestinal tracts of many species, from insects to humans (1), but are also the third leading cause of hospital infections (2, 3). They display intrinsic and acquired resistance to almost all antibiotics in clini- cal use, and no single agent is able to kill more than 3 log10 CFU/g in vivo (4). Animal models of infection are invaluable tools for anti-infective pharmacology, and numerous in vivo enterococcal models have been used to test old and new drugs, but their vali- dation for assessing the efficacy of antimicrobial agents is fre- quently not reported (5). The enterococcal endocarditis rabbit model is perhaps used the most, but it is also more expensive, cumbersome, and centered on a tissue with complex pharmaco- kinetics (i.e., cardiac valves), limiting its relevance for other sys- temic infections (6). Additionally, the usual lack of a full dose- response curve hinders the determination of pharmacokinetic/ pharmacodynamic (PK/PD) indices necessary to translate the results to humans (5, 7). Moreover, the bacterial growth in all enterococcal models is either not quantified (e.g., peritonitis model) (8), poor (�1 log10 CFU/g), or even negative (e.g., thigh infection) (9, 10), and the variability is high (e.g., rabbit endocar- ditis models) (11), particularly with vancomycin (VAN)-resistant enterococcus (VRE) strains (12). Negligible growth and high-level dispersion may lead to inaccurate estimations of antibiotic PD, as has been the case with daptomycin (13). We optimized the in vitro culture conditions for enterococci by using anaerobic incubation and mucin supplementation, aiming to enhance the in vivo growth of vancomycin-susceptible entero- coccus (VSE) and VRE strains and to determine its impact on the PD of three antibiotics: VAN, ampicillin-sulbactam (SAM), and piperacillin-tazobactam (TZP). (Different aspects of this work were presented at the 3rd ASM International Conference on Enterococci and at the 51st and 53rd ICAAC [14–16].) MATERIALS AND METHODS Bacterial strains, antibiotics, and susceptibility testing. The wild-type strains Enterococcus faecalis ATCC 29212 and E. faecium ATCC 19434 and the vancomycin-resistant strains E. faecalis ATCC 51299 (VanB) and E. faecium ATCC 51559 (VanA) were used from vials stored at �70°C. VRE strains were tested after optimizing the experimental conditions with VSE. We determined the MICs of VAN (Vancocin CP; Baxter, Brazil), SAM (Unasyn; Pfizer, Italy), and TZP (Tazocin; Wyeth Lederle, Italy) by broth microdilution following CLSI methods (17). Although the studied strains were beta-lactamase negative, ampicillin (AMP) and piperacillin (PIP) were used as combinations with beta-lactamase inhibitors. Inoculum preparation. Strains were stored at �70°C and recovered by two successive streaks on brain heart infusion (BHI) agar (Becton Dickinson) with 5% sheep blood, followed by incubation for 24 h at 37°C under ambient air (aerobic groups) or by placing the plates within a sealed anaerobiosis bag (GazPak EZ; Becton Dickinson) in a 10% CO2 incubator (anaerobic groups). The GazPak EZ system provides an atmosphere with �1% oxygen and �13% CO2 within 24 h. We named this step “phase 0.” Before in vivo experiments, we standardized the in vitro growth kinet- ics under aerobic and anaerobic incubation conditions in broth to define the time and optical density at 580 nm (OD580) (Spectro 22H; Labomed Inc., Culver City, CA) required to reach �8 log10 CFU/ml in the log phase (data not shown). For all strains, 3 to 5 colonies from phase 0 were sus- pended in 10 ml of broth, serially diluted 4 times (1:10), and incubated overnight at 37°C, keeping the atmosphere the same as in the previous step (phase 1). The most diluted tube with complete turbidity was se- lected, diluted further (1:100) in fresh broth, and incubated using the same atmosphere as that from phase 1, until it reached an OD580 corre- Received 28 October 2013 Returned for modification 9 December 2013 Accepted 17 October 2014 Accepted manuscript posted online 27 October 2014 Citation Rodriguez CA, Agudelo M, Gonzalez JM, Vesga O, Zuluaga AF. 2015. An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics. Antimicrob Agents Chemother 59:233–238. doi:10.1128/AAC.02352-13. Address correspondence to Andres F. Zuluaga, andres.zuluaga@udea.edu.co. Supplemental material for this article may be found at http://dx.doi.org/10.1128 /AAC.02352-13. Copyright © 2015, American Society for Microbiology. All Rights Reserved. doi:10.1128/AAC.02352-13 January 2015 Volume 59 Number 1 aac.asm.org 233Antimicrobial Agents and Chemotherapy http://orcid.org/0000-0001-5656-4153 http://dx.doi.org/10.1128/AAC.02352-13 http://dx.doi.org/10.1128/AAC.02352-13 http://dx.doi.org/10.1128/AAC.02352-13 http://dx.doi.org/10.1128/AAC.02352-13 http://aac.asm.org sponding to �8.0 log10 CFU/ml (phase 2). The broths used in phases 1 and 2 were BHI (Becton Dickinson) for the aerobic groups and thiogly- colate USP (a reducing medium from Oxoid, United Kingdom) for the anaerobic groups. Bacteria from phase 2 were diluted in the correspond- ing medium to the desired final inoculum size, which varied from 5 to 8 log10 CFU/ml according to the experiment. In some in vivo experiments (described below), the inoculum from phase 2 was supplemented with mucin just before inoculation by mixing autoclaved 10% (wt/vol) porcine stomach mucin (Sigma-Aldrich) with the culture broth (BHI or thiogly- colate) in equal volumes, obtaining a final mucin concentration of 5% (18). Animal model. The University of Antioquia Animal Experimentation Ethics Committee reviewed and approved the experimental protocol. Six- week-old murine-pathogen-free female mice of the strain Udea:ICR(CD- 2), weighing 23 to 27 g, were rendered neutropenic (�100 neutrophils/ mm3) by intraperitoneal injection of two doses of cyclophosphamide (Endoxan; Baxter, Germany), given 4 days (150 mg/kg of body weight) and 1 day (100 mg/kg) before infection (19). Sixteen hours later, isoflu- rane (Isorane; Abbott, Argentina)-anesthetized animals were infected in- tramuscularly in each thigh with 0.1 ml of the selected inoculum. During the standardization of the model, mice were separated into four experi- mental groups (n � 10 animals/group) according to the inoculum condi- tions used, as follows: aerobiosis (nonsupplemented broth), aerobiosis plus mucin (incubated under an aerobic atmosphere in broth supple- mented with 5% porcine mucin), anaerobiosis (nonsupplemented broth), and anaerobiosis plus mucin (incubated under an anaerobic at- mosphere in broth supplemented with 5% mucin). A minimum of two animals per group were picked from their cages at random and sacrificed immediately after inoculation (0 h), at five or more time points (1, 2, 4, 6, 8, 10, 12, 14, and/or 18 h), and by the end of the model (26 h after infec- tion). Thighs were aseptically removed, homogenized (PRO200 tissue ho- mogenizer; ProScientific), diluted, and automatically plated (DS� spiral plater; Interscience, France). Bacterial counting (Scan 500 automatic col- ony counter; Interscience, France) was done after 20 h of incubation at 37°C in ambient air. Earlier experiments showed that there was no signif- icant difference in bacterial counts for thigh samples plated on BHI agar incubated under aerobiosis or anaerobiosis conditions (data not shown). All experiments were performed at least twice. If not specified otherwise, each symbol in all figures represents the geometric mean of results for both thighs from one mouse. To control for the potential effect of the broth supplement on the animals, a group of 10 neutropenic mice were injected in the thighs with sterile 5% mucin and examined daily for signs of local or systemic toxicity for 10 days. To elucidate further the contribution of mucin to the development of the model, groups of immunocompetent mice were infected with E. faeca- lis ATCC 29212 prepared under anaerobiosis or anaerobiosis-plus-mucin conditions. To reduce the number of animals used in this case, the mice were sacrificed only 0, 1, 2, 14, and 26 h after infection. Impact of culture conditions on systemic dissemination. To mea- sure the impact of inoculum preparation on systemic dissemination, we sacrificed at least 7 neutropenic mice from two independent experiments to quantify bacterial dissemination to the blood and spleen 26 h after infection with E. faecium ATCC 19434 prepared under conditions of aer- obiosis, aerobiosis plus mucin, or anaerobiosis plus mucin. Each spleen was homogenized and diluted to 1 ml in sterile saline before plating; blood (0.1 ml) was plated directly on the agar. The limits of detection were 1 log10 CFU per ml of blood and 2.3 log10 CFU per gram of spleen. Impact of inoculum conditions on antimicrobial pharmacodynam- ics. Neutropenic mice were infected with E. faecium ATCC 19434 (VAN and SAM) or E. faecalis ATCC 29212 (TZP) prepared under conditions of aerobiosis, aerobiosis plus mucin, or anaerobiosis plus mucin. Subcuta- neous treatment (0.2 ml) started at 2 h postinfection, allocating 2 mice per dose and encompassing at least 6 doses from no effect to maximal effect. The doses ranged from 2.34 to 600, 18.75 to 2,400, and 18.75 to 4,800 mg/kg/day for VAN, SAM, and TZP, respectively, in all cases divided every 3 h (q3h). At the end of treatment, the thighs of each mouse were dissected aseptically, homogenized independently, serially diluted, plated, and in- cubated overnight at 37°C. The limit of detection was 100 CFU/thigh, which in this model was equivalent to 2 log10 CFU/g. In addition, we included six untreated control mice per experiment; these received 0.2-ml subcutaneous injections of sterile saline q3h and were sacrificed and pro- cessed in the same way as the experimental groups at 3 time points: just after inoculation (�2 h) and at the onset (0 h) and end (24 h) of therapy. Statistical analysis. Bacterial counts were stored in an Excel database (Microsoft, Seattle, WA) for subsequent analysis. In vivo growth (G) was established by use of an empirical equation and as a parameter derived from nonlinear regression (NLR). In the former case, the net growth (�G26�2) was defined simply by subtraction of the mean number of bac- teria observed 2 h after infection from that reached at 26 h (19, 20). In the latter case, in vivo growth-time curves were fitted using an NLR analysis described by a modified Gompertz equation (see Table S1 in the supple- mental material) (21). The magnitudes of the parameters derived from this equation were compared by curve-fitting analysis (CFA; Prism 6.04) (22, 23). A successful in vivo model was defined as one that attained the following four criteria: (i) net growth (�G26�2) of �1.5 log10 CFU/g, (ii) significant parameters derived from Gompertz’s equation that fulfilled the homoscedasticity and normality assumptions, (iii) a difference be- tween the maximal and minimal predicted bacterial counts of �2 log10 CFU/g (see the Auctus column in Table S1), and (iv) a standard error of the estimate (Sy�x) of �0.5 log10. Dissemination data for the blood and spleen at 26 h postinfection were compared by analysis of variance (ANOVA) for normally distributed data (see Fig. S1 in the supplemental material); otherwise, the Kruskal-Wallis (KW) test was used. For PD data, the net antibacterial effect (dependent variable) of each product’s dose (independent variable) was calculated by subtracting the number of CFU/g for untreated controls at 24 h from the number of CFU/g remaining in treated mice. Hill’s equation was fitted to these data to describe the sigmoid dose-response relationship and to estimate the primary PD (PDP) parameters maximum effect (Emax), 50% effective dose (ED50), and Hill’s slope (N), as we have described elsewhere (23, 24). A parameter was considered invalid if the nonlinear regression failed any of the presumptions of normality, homoscedasticity, or nonmulticolin- earity. Additionally, the secondary parameters bacteriostatic dose (BD) and maximal kill dose (MKD) were calculated (23). For PK analysis, we used data from our previous studies of infected ICR mice treated with VAN, piperacillin, and ampicillin (24–26), fitted with Pmetrics by using the nonparametric adaptive grid (NPAG) algorithm, to obtain the popu- lation PK parameters (27). For PK/PD analysis, the area under the con- centration-time curve for the free, unbound fraction of the drug (fAUC) between 0 h and 24 h (VAN) and the time in a 24-h period that the drug concentration for the free, unbound fraction exceeded the MIC under steady-state pharmacokinetic conditions (fT�MIC) (AMP and PIP) were calculated using ADAPT 5 (28, 29). For these calculations, we used pro- tein binding levels in mice of 29%, 20%, and 3% for VAN, PIP, and AMP, respectively (24, 30, 31). PD parameters were compared by curve-fitting analysis (23). RESULTS Impacts of the atmosphere of incubation, mucin supplementa- tion, and immune status on in vivo growth. Figure 1 illustrates that anaerobiosis-plus-mucin conditions were required with E. faecalis 29212 (�5 log10 CFU/g) to achieve a successful in vivo model (as defined in Materials and Methods) in neutropenic (Fig. 1a) and immunocompetent (Fig. 1c) mice. The net growth under aerobiosis-plus-mucin conditions was enhanced in neutropenic mice (Fig. 1b) (mean �G26�2 2.07 log10 CFU/g), but the regres- sion failed the assumption of homoscedasticity (no fit to Gomp- ertz’s equation). In immunocompetent mice (Fig. 1c), anaerobi- osis without mucin led to exponential decay of the bacterial count Rodriguez et al. 234 aac.asm.org January 2015 Volume 59 Number 1Antimicrobial Agents and Chemotherapy http://aac.asm.org (below the limit of detection), with complete clearance of infec- tion after 14 h. Due to the low growth, high error, and high simi- larity to aerobiosis encountered with the anaerobiosis condition (see Table S1 in the supplemental material), it was not tested any- more. The comparison of immunocompetent and neutropenic mice for anaerobiosis plus mucin (inoculum of �4 log10 CFU per thigh) in- dicated that neutropenia enhanced the �G26�2 by 1.26 log10 CFU/g. The results with other strains are summarized in Table S1 in the sup- plemental material. The animals injected with 5% sterile mucin had swelled thighs without signs of systemic illness during the first day, after which the inflammation resolved completely. On day 10 after mucin injection, all mice were alive and healthy. Impact of mucin on systemic dissemination of E. faecium ATCC 19434. Taking into account the similar levels of in vivo growth reached in mice inoculated with E. faecium 19434 under anaerobiosis-plus-mucin versus aerobiosis-plus-mucin condi- tions (see Table S1 in the supplemental material), we compared the levels of dissemination to distant organs 26 h after infection. Higher bacterial burdens in the spleen (P � 0.001 by ANOVA) and blood (P 0.0002 by KW test) were observed for anaerobiosis plus mucin (see Fig. S1 for details). Antimicrobial pharmacodynamics. The MICs of VAN and SAM against E. faecium 19434 were 1 and 2 mg/liter, respectively; against E. faecalis 29212, the MIC of TZP was 2 mg/liter. The PK parameters of VAN, AMP, and PIP on infected neutropenic mice are shown in Table 1, and the PD parameters of VAN, SAM, and TZP obtained using different inoculum conditions are shown in Table 2. In all cases, mucin supplementation led to high in vivo growth (�G26�2 � 1.85 log10 CFU/g) and yielded significant PD parameters (adjusted R2 � 0.94). In contrast, the aerobiosis group displayed minimal net growth (�G26�2 � 0.41 log10 CFU/g) and did not fit Hill’s equation with VAN (adjusted R2 0.25) and TZP (adjusted R2 0.31), showing erratic PD profiles (Fig. 2a and b). For SAM (adjusted R2 0.84), aerobiosis (Fig. 2c) displayed in- valid parameters with a high multicolinearity (variance inflation factor [VIF] of �166 for the bacteriostatic dose). Regarding the pharmacodynamics of VAN against E. faecium 19434 (Fig. 2a), there were statistically significant differences in the primary parameters (Emax, ED50, and N) between the aerobiosis- plus-mucin and anaerobiosis-plus-mucin groups (P � 0.0001 by global CFA). Moreover, it was not possible to estimate a valid MKD under aerobiosis-plus-mucin conditions due to high multicolinearity (VIF 30). Similar to the case for VAN, the PD of TZP against E. faecalis 29212 (Fig. 2b) changed depending on the group tested, and there were significant differences (P � 0.0001 by global CFA) in PD parameters (Table 2) in comparing aerobiosis plus mucin and anaerobiosis plus mucin. Specifically, the magnitude of the expo- sure required for stasis was significantly lower for aerobiosis plus mucin than for anaerobiosis plus mucin (BD 23.5% versus 32.0% in terms of fT�MIC). Finally, SAM was highly bactericidal against E. faecium 19434 (Fig. 2c), and anaerobiosis plus mucin was necessary to calculate the exposure required (in terms of fT�MIC) to kill 4 log bacteria (MKD) (Table 2). In contrast, aerobiosis plus mucin yielded an invalid parameter. DISCUSSION At least two problems characterize the available animal models of enterococcal infection: minimal bacterial growth and a high level FIG 1 Impacts of atmosphere of incubation, mucin supplementation, and immune status on the in vivo growth of E. faecalis ATCC 29212. In all panels, solid lines represent significant and valid regressions using Gompertz’s equation, and dotted lines indicate that the regression did not fit or failed the presumptions of normality or homoscedasticity (see Table S1 in the supplemental material). (a) Growth in neutropenic mice infected with inocula prepared under conditions of anaerobiosis (dotted gray line) or anaerobiosis plus mucin (solid black line). (b) Growth in neutropenic mice infected with inocula prepared under conditions of aerobiosis (dotted gray line) or aerobiosis plus mucin (black dotted line). (c) In vivo growth curves for immunocompetent animals infected with inocula prepared under conditions of anaerobiosis plus mucin (solid black line) or anaerobiosis (gray interrupted line). In panel c, data points at 26 h (black) and 14 and 26 h (gray) overlap. TABLE 1 Pharmacokinetic parameters in infected mice, derived from a two-compartment model for vancomycin and ampicillin or a one- compartment model for piperacillina Parameter Value Vancomycin Ampicillin Piperacillin kel (h�1) 1.67 20.4 3.16 Vc (liters) 0.01 0.01 0.04 kcp (h�1) 3.16 78.2 NA kpc (h�1) 62.8 15.0 NA ka (h�1) 2.52 6.45 7.45 a Using data from references 24 to 26. Abbreviations: kel, elimination rate constant; Vc, volume of the central compartment; kcp, transfer rate constant from the central to peripheral compartment; kpc, transfer rate constant from the peripheral to central compartment; ka, absorption rate constant; NA, not applicable. Optimized Enterococcal Murine Infection Model January 2015 Volume 59 Number 1 aac.asm.org 235Antimicrobial Agents and Chemotherapy http://aac.asm.org of data dispersion (8–13). Here we solved these problems by using anaerobiosis plus mucin to attain an optimized thigh infection model suitable for PD studies. Previously, Safdar et al. evaluated the PD of daptomycin against Staphylococcus aureus, Streptococcus pneumoniae, and E. faecium cultured under aerobic conditions without mucin supple- mentation (13). They concluded that more studies with strains that grew better were needed because low growth (�G26�2 � 0.4 log10 CFU/g) led to overestimation of the drug’s efficacy against E. faecium (AUC/MIC for stasis was 0.94 to 1.67) compared to that with S. aureus (388 to 537) or S. pneumoniae (75 to 237) (13). Other authors have obtained similarly biased results (9). Our data demonstrate that only anaerobiosis-plus-mucin con- ditions yielded high tissue growth and the excellent fit with signif- icant parameters required to define the exposure-response rela- tionship. In contrast, the use of aerobiosis plus mucin yielded a questionably low magnitude of exposure required for stasis with TZP compared with the values reported for other beta-lactams (�30% for BD) (32), and in the case of VAN and SAM, it was not possible to estimate the maximum killing dose. We have several hypotheses that may explain the importance of anaerobiosis plus mucin for attaining a successful in vivo model and that deserve to be tested in the future. Previous studies have found differential gene expression in enterococci according to the incubation atmosphere (33). Day et al. showed that there are three different phenotypic profiles of cytolysin expression in E. faecalis, based on the atmosphere of incubation (34). We found that E. faecalis ATCC 29212 corresponds to Day et al.’s phenotype 2 (data not shown), meaning that beta-hemolysis appears only under an anaerobic atmosphere. In particular, this toxin in enterococci has been characterized as a heat-labile, oxygen-stable molecule (35), suggesting that it is available to induce damage in vivo even after the atmosphere switches. Regarding mucin, it is a heavily glycosy- lated cysteine-rich protein that covers the epithelium of the gas- trointestinal tract and is a potential natural source of amino acids and sugars for enterococci (36–39). There has been at least one previous attempt to improve the enterococcal thigh infection model. Eguchi et al. supplemented the inoculum with carrageenan, a tissue irritant used in models of inflammatory pain, enhancing net growth (�G26�2 1.41 log) in neutropenic mice but also increasing the standard deviation (SD 1.04 log10 CFU/g at 26 h) (40). We think that our model with anaerobiosis plus mucin is better because it enhanced the net growth of susceptible and resistant strains (�G26�2 � 1.6 log) (see Table S1 in the supplemental material) without increasing the dispersion of the data (coefficient of variation of �40%, versus 74% for the work of Eguchi et al.). This is a major point, because the power of any statistical method for quantitative variables and the estimation of the sample size are critically dependent on the standard deviation of the data. As a novelty of our approach, mu- cin enhanced growth even in immunocompetent mice, probably by a protective “coating effect” on bacteria (41). TABLE 2 Pharmacodynamics of VAN, TZP, and SAM against enterococci under different inoculum conditionsa Parameter Value VAN vs E. faecium 19434 TZP vs E. faecalis 29212 SAM vs E. faecium 19434 Aerobiosis Aerobiosis � mucin Anaerobiosis � mucin Aerobiosis Aerobiosis � mucin Anaerobiosis � mucin Aerobiosis Aerobiosis � mucin Anaerobiosis � mucin Emax (log10 CFU/g) IVP 3.34 0.07 3.05 0.07 IVP 4.37 0.12 4.86 0.12 3.75 0.26 6.36 0.37 6.80 0.23 ED50 (mg/kg/day) IVP 18.5 0.77 26.0 1.62 IVP 215 9.94 425 19.0 122 19.3 259 30.9 218 10.9 N IVP 3.03 0.36 5.27 0.91 IVP 4.53 0.57 3.64 0.41 2.18 0.71 2.39 0.58 3.53 0.46 BD IVP 44.3 2.29 52.8 2.91 IVP 23.5 0.50 32.0 0.40 IVP 31.3 2.23 28.3 0.89 MKD IVP IVP 83.6 9.82 IVP 34.2 1.77 41.1 1.29 IVP IVP 45.7 2.16 a Abbreviations: Emax, maximum effect; ED50, 50% effective dose; N, Hill’s slope; BD, bacteriostatic dose in terms of fAUC/MIC (VAN) or fT�MIC (SAM and TZP); MKD, the dose (exposure) required for maximal killing of 0.8 log (VAN), 2.3 log (TZP), and 4 log (SAM) bacteria in terms of fAUC/MIC (VAN) or fT�MIC (SAM and TZP). All values are presented as means standard errors. IVP, invalid parameter because it was not possible to fit Hill’s equation to data or the nonlinear regression failed any of the presumptions of normality, homoscedasticity, and nonmulticolinearity (variance inflation factor of �10). FIG 2 Pharmacodynamics of vancomycin (a), piperacillin-tazobactam (b), and ampicillin-sulbactam (c) in the following groups: aerobiosis (gray triangles and lines), aerobiosis plus mucin (red circles and lines), and anaerobiosis plus mucin (black squares and lines). For the aerobiosis group (gray triangles), no antibiotic fit Hill’s equation in terms of fAUC/MIC (VAN) or fT�MIC (SAM and TZP) against E. faecium ATCC 19434 or E. faecalis ATCC 29212. Rodriguez et al. 236 aac.asm.org January 2015 Volume 59 Number 1Antimicrobial Agents and Chemotherapy http://aac.asm.org To our knowledge, this is the first in vivo report of the magni- tudes of the PD index fAUC/MIC of VAN against E. faecium necessary for stasis (52.8 2.91) and maximal bacterial killing (83.6 9.82). In fact, the only previous data regarding the in vivo PD of VAN came from a retrospective clinical study, which found that an fAUC/MIC of 87 (adjusted by 30% protein binding) was necessary for a satisfactory clinical outcome of Gram-positive in- fections (42). The similarity of these magnitudes between mice and humans is remarkable and constitutes a case of predictive validation of our optimized model (5, 43). Although there are no reports of PD indices of TZP and SAM against enterococci, the fT�MIC magnitudes found here were similar to those reported for other penicillins (32, 44). In conclusion, we have validated an animal model, optimized by preparing the inoculum under anaer- obic conditions and supplementing it with mucin (5), that is use- ful for accurately assessing antimicrobial PD against enterococci. ACKNOWLEDGMENTS This project was funded by the Colombian Government Department of Science, Technology and Innovation (Colciencias) (grant 111540820499) and by the University of Antioquia (Estrategia de Sostenibilidad 2013– 2014). We do not have conflicts of interest. We thank Jefferson Perez and Alexis Santamaria for animal care sup- port and for participation during some of the experimental procedures. REFERENCES 1. Gilmore MS, Coburn PS, Nallapareddy SR, Murray BE. 2002. Entero- coccal virulence, p 301–354. In Gilmore MS (ed), The enterococci: patho- genesis, molecular biology, and antibiotic resistance. ASM Press, Wash- ington, DC. 2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare- associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Preven- tion, 2006 –2007. Infect Control Hosp Epidemiol 29:996 –1011. http://dx .doi.org/10.1086/591861. 3. Huycke MM. 2002. Physiology of enterococci, p 133–175. In Gilmore MS (ed), The enterococci: pathogenesis, molecular biology, and antibiotic resistance. ASM Press, Washington, DC. 4. Houlihan HH, Stokes DP, Rybak MJ. 2000. Pharmacodynamics of van- comycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. J Antimicrob Chemother 46:79 – 86. http://dx.doi.org/10.1093/jac /46.1.79. 5. Zuluaga AF, Rodriguez CA, Agudelo M, Vesga O. 2014. About the validation of animal models to study the pharmacodynamics of generic antimicrobials. Clin Infect Dis 59:459 – 461. http://dx.doi.org/10.1093/cid /ciu306. 6. Fantin B, Leclercq R, Arthur M, Duval J, Carbon C. 1991. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vanco- mycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother 35:1570 –1575. http://dx.doi.org /10.1128/AAC.35.8.1570. 7. Sande MA. 1981. Evaluation of antimicrobial agents in the rabbit model of endocarditis. Rev Infect Dis 3(Suppl):S240 –S249. 8. Arias CA, Singh KV, Panesso D, Murray BE. 2007. Evaluation of cefto- biprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 60:594 –598. http://dx.doi.org/10.1093 /jac/dkm237. 9. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP. 2003. Pharmacodynamic profile of daptomycin against Enterococcus spe- cies and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52:405– 411. http://dx.doi.org /10.1093/jac/dkg337. 10. Griffith DC, Rodriguez D, Corcoran E, Dudley MN. 2008. Pharmaco- dynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh in- fection model. Antimicrob Agents Chemother 52:244 –247. http://dx.doi .org/10.1128/AAC.00776-07. 11. Lefort A, Lafaurie M, Massias L, Petegnief Y, Saleh-Mghir A, Muller- Serieys C, Le Guludec D, Fantin B. 2003. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 47:216–222. http://dx.doi.org/10.1128/AAC.47.1.216-222.2003. 12. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. 2006. Efficacy of daptomycin in the treatment of experimental endocarditis due to suscep- tible and multidrug-resistant enterococci. J Antimicrob Chemother 58: 1208 –1214. http://dx.doi.org/10.1093/jac/dkl406. 13. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48:63– 68. http://dx.doi .org/10.1128/AAC.48.1.63-68.2004. 14. Santamaria A, Rodriguez CA, Agudelo M, Vesga O, Zuluaga AF. 2010. Abstr 3rd Int ASM Conf Enterococci, Portland, Oregon, p 33–34. 15. Zuluaga AF, Agudelo M, Perez JA, Gonzalez JM, Rodriguez CA, Vesga O. 2011. Successful models of thigh infection in neutropenic mice by vancomycin-susceptible (VSE) and -resistant enterococci (VRE), abstr B-056. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. ASM Press, Washington, DC. 16. Zuluaga AF, Rodriguez CA, Perez JA, Gonzalez JM, Vesga O. 2013. Redefining the pharmacodynamics of three antienterococcal drugs in the optimized neutropenic mouse thigh infection model, abstr A-018. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO. ASM Press, Washington, DC. 17. CLSI. 2013. Performance standards for antimicrobial susceptibility test- ing: twenty-third informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA. 18. Lorian V. 2005. Antibiotics in laboratory medicine, 5th ed, p 670. Lippin- cott William & Wilkins, Philadelphia, PA. 19. Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 6:55. http://dx .doi.org/10.1186/1471-2334-6-55. 20. Gudmunsson S, Erlensdóttir H. 1999. Murine thigh infection model, p 137–144. In Zak O, Sande MA (ed), Handbook of animal models of infec- tion. Academic Press, San Diego, CA. 21. Zwietering MH, Jongenburger I, Rombouts FM, van’t Riet K. 1990. Modeling of the bacterial growth curve. Appl Environ Microbiol 56:1875– 1881. 22. Glantz SA. 2005. Primer of biostatistics, 6th ed. McGraw-Hill Medical Publishing, New York, NY. 23. Zuluaga AF, Agudelo M, Cardeno JJ, Rodriguez CA, Vesga O. 2010. Determination of therapeutic equivalence of generic products of gentami- cin in the neutropenic mouse thigh infection model. PLoS One 5:e10744. http://dx.doi.org/10.1371/journal.pone.0010744. 24. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 54:3271– 3279. http://dx.doi.org/10.1128/AAC.01044-09. 25. Rodriguez CA, Agudelo M, Gonzalez M, Zuluaga AF, Vesga O. 2013. Generic piperacillin-tazobactam (TZP) enriches resistant subpopulations of Escherichia coli after exposure in the neutropenic mouse thigh infection model (NMTIM), abstr A-479. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO. ASM Press, Washington, DC. 26. Zuluaga AF, Salazar BE, Loaiza SA, Agudelo M, Vesga O. 2004. Ther- apeutic equivalence with the original compound of 8 generic products of ampicillin determined in the neutropenic murine thigh infection model, abstr E-2033. Abstr 44th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC. 27. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. 2012. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simula- tion package for R. Ther Drug Monit 34:467– 476. http://dx.doi.org/10 .1097/FTD.0b013e31825c4ba6. 28. D’Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedi- cal Simulations Resource, Los Angeles, CA. 29. Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL. 2010. The combination of meropenem and levofloxacin is Optimized Enterococcal Murine Infection Model January 2015 Volume 59 Number 1 aac.asm.org 237Antimicrobial Agents and Chemotherapy http://dx.doi.org/10.1086/591861 http://dx.doi.org/10.1086/591861 http://dx.doi.org/10.1093/jac/46.1.79 http://dx.doi.org/10.1093/jac/46.1.79 http://dx.doi.org/10.1093/cid/ciu306 http://dx.doi.org/10.1093/cid/ciu306 http://dx.doi.org/10.1128/AAC.35.8.1570 http://dx.doi.org/10.1128/AAC.35.8.1570 http://dx.doi.org/10.1093/jac/dkm237 http://dx.doi.org/10.1093/jac/dkm237 http://dx.doi.org/10.1093/jac/dkg337 http://dx.doi.org/10.1093/jac/dkg337 http://dx.doi.org/10.1128/AAC.00776-07 http://dx.doi.org/10.1128/AAC.00776-07 http://dx.doi.org/10.1128/AAC.47.1.216-222.2003 http://dx.doi.org/10.1093/jac/dkl406 http://dx.doi.org/10.1128/AAC.48.1.63-68.2004 http://dx.doi.org/10.1128/AAC.48.1.63-68.2004 http://dx.doi.org/10.1186/1471-2334-6-55 http://dx.doi.org/10.1186/1471-2334-6-55 http://dx.doi.org/10.1371/journal.pone.0010744 http://dx.doi.org/10.1128/AAC.01044-09 http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6 http://dx.doi.org/10.1097/FTD.0b013e31825c4ba6 http://aac.asm.org synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother 54:2646 –2654. http://dx.doi.org/10.1128/AAC.00065-10. 30. van Ogtrop ML, Mattie H, Sekh BR, van Strijen E, van Furth R. 1992. Comparison of the antibacterial efficacies of ampicillin and ciprofloxacin against experimental infections with Listeria monocytogenes in hydrocor- tisone-treated mice. Antimicrob Agents Chemother 36:2375–2380. http: //dx.doi.org/10.1128/AAC.36.11.2375. 31. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 56:544 –549. http://dx.doi.org/10.1128/AAC.01752-10. 32. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clin- ical applications to the use of beta-lactams, glycopeptides, and lin- ezolid. Infect Dis Clin North Am 17:479 –501. http://dx.doi.org/10 .1016/S0891-5520(03)00065-5. 33. Shepard BD, Gilmore MS. 1999. Identification of aerobically and anaer- obically induced genes in Enterococcus faecalis by random arbitrarily primed PCR. Appl Environ Microbiol 65:1470 –1476. 34. Day AM, Cove JH, Phillips-Jones MK. 2003. Cytolysin gene expression in Enterococcus faecalis is regulated in response to aerobiosis conditions. Mol Genet Genomics 269:31–39. http://dx.doi.org/10.1007/s00438-003 -0819-1. 35. Van Tyne D, Martin MJ, Gilmore MS. 2013. Structure, function, and biology of the Enterococcus faecalis cytolysin. Toxins 5:895–911. http://dx .doi.org/10.3390/toxins5050895. 36. Pultz NJ, Hoskins LC, Donskey CJ. 2006. Vancomycin-resistant entero- cocci may obtain nutritional support by scavenging carbohydrate frag- ments generated during mucin degradation by the anaerobic microbiota of the colon. Microb Drug Resist 12:63– 67. http://dx.doi.org/10.1089 /mdr.2006.12.63. 37. Corfield AP, Wagner SA, Clamp JR, Kriaris MS, Hoskins LC. 1992. Mucin degradation in the human colon: production of sialidase, sialate O-acetylesterase, N-acetylneuraminate lyase, arylesterase, and glycosulfa- tase activities by strains of fecal bacteria. Infect Immun 60:3971–3978. 38. Monti E, Bonten E, D’Azzo A, Bresciani R, Venerando B, Borsani G, Schauer R, Tettamanti G. 2010. Sialidases in vertebrates: a family of enzymes tailored for several cell functions. Adv Carbohydr Chem Biochem 64:403– 479. http://dx.doi.org/10.1016/S0065-2318(10)64007-3. 39. Monti E, Preti A, Venerando B, Borsani G. 2002. Recent development in mammalian sialidase molecular biology. Neurochem Res 27:649 – 663. http://dx.doi.org/10.1023/A:1020276000901. 40. Eguchi K, Kanazawa K, Eriguchi Y, Ueda Y. 2009. Pharmacodynamics of SMP-601 (PTZ601) against vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in neutropenic murine thigh infection models. Antimicrob Agents Chemother 53:3391–3398. http://dx.doi.org/10.1128/AAC.00972-08. 41. Olitzki L. 1948. Mucin as a resistance-lowering substance. Bacteriol Rev 12:149 –172. 42. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. 1995. The impor- tance of pharmacokinetic/pharmacodynamic surrogate markers to out- come. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160. 43. Varga OE, Hansen AK, Sandoe P, Olsson IA. 2010. Validating animal models for preclinical research: a scientific and ethical discussion. Altern Lab Anim 38:245–248. 44. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: ratio- nale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10. http://dx.doi.org/10.1086/516284. Rodriguez et al. 238 aac.asm.org January 2015 Volume 59 Number 1Antimicrobial Agents and Chemotherapy http://dx.doi.org/10.1128/AAC.00065-10 http://dx.doi.org/10.1128/AAC.36.11.2375 http://dx.doi.org/10.1128/AAC.36.11.2375 http://dx.doi.org/10.1128/AAC.01752-10 http://dx.doi.org/10.1016/S0891-5520(03)00065-5 http://dx.doi.org/10.1016/S0891-5520(03)00065-5 http://dx.doi.org/10.1007/s00438-003-0819-1 http://dx.doi.org/10.1007/s00438-003-0819-1 http://dx.doi.org/10.3390/toxins5050895 http://dx.doi.org/10.3390/toxins5050895 http://dx.doi.org/10.1089/mdr.2006.12.63 http://dx.doi.org/10.1089/mdr.2006.12.63 http://dx.doi.org/10.1016/S0065-2318(10)64007-3 http://dx.doi.org/10.1023/A:1020276000901 http://dx.doi.org/10.1128/AAC.00972-08 http://dx.doi.org/10.1086/516284 http://aac.asm.org An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics MATERIALS AND METHODS Bacterial strains, antibiotics, and susceptibility testing. Inoculum preparation. Animal model. Impact of culture conditions on systemic dissemination. Impact of inoculum conditions on antimicrobial pharmacodynamics. Statistical analysis. RESULTS Impacts of the atmosphere of incubation, mucin supplementation, and immune status on in vivo growth. Impact of mucin on systemic dissemination of E. faecium ATCC 19434. Antimicrobial pharmacodynamics. DISCUSSION ACKNOWLEDGMENTS REFERENCES